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Beclomethasone dipropionate CFC free inhalation formulations were developed with a view to treat 
asthma prophylactically. Dry powder inhalers (DPI) for beclomethasone dipropionate were prepared with 
different grades of lactose monohydrate. The influence of carrier and overages on performance of DPI 
was studied. Metered dose inhalers (MDI) with HFA based propellants were formulated with various 
doses, overages and different concentrations of alcohol. Formulated DPI and MDI were evaluated for 
various official and unofficial quality control tests. The influence of over doses on valve delivery, effect 
of overages on emitted dose and influence of alcohol on spray pattern from MDI were studied. The 
better fine particle fraction and emitted dose were obtained from the DPI formulated with 10:90 ratio of 
fine lactose: coarse lactose and with 20% w/w overages. The studies on MDI revealed that the 15% of 
overdoses are required for effective valve delivery and 20% overages are required for 100% drug delivery. 
5-10%v/v alcohol was found to be preferable to get optimum emitted dose and fine particle fraction.
Uniterms: Beclomethasone dipropionate. Dry powder inhalers. Metered dose inhalers,, emmited dose. 
Fine particle fraction, overages
Desenvolveram-se formulações por inalação de dipropionato de beclometasona, livres de CFC, com o 
objetivo de tratar a asma profilaticamente. Prepararam-se inaladores de pó seco (DPI) para o dipropionato 
de beclometasona com diferentes gradações de lactose monoidratada. Estudou-se a influência do 
transportador e dos excessos de fármaco em relação ao rotulado no desempenho do DPI. Inaladores de 
dose calibrada (MDI) com propelentes à base de hidrofluoralcanos (HFA) foram formulados com várias 
doses, excessos de fármaco em relação ao rotulado e diferentes concentrações de álcool. Avaliaram-se as 
DPI e MDI formuladas por vários métodos oficiais e não oficiais de controle de qualidade. Estudaram-se 
a influência da superdosagem na liberação da válvula, o efeito dos excessos na dose emitida e a influência 
do álcool no padrão do spray do MDI. Obtiveram-se a melhor partícula fina e a dose emitida do DPI 
formulado com proporção de 10:90 de lactose fina:lactose grossa e 20% p/p de excesso. Os estudos 
em MDI revelaram que 15% de sobredose são requeridos para a liberação efetiva da válvula e 20% de 
excessos, para a liberação de 100% dos fármacos. Álcool a 5-10% v/v permitiu alcançar ótima dose 
emitida e fração de partícula fina.
Unitermos: Dipropionato de beclometasona. Inaladores pó seco. Inalantes de dose cvalibrada, dose 
emitida. Fração de partículas finas, excessos. 
INTRODUCTION
Nowadays, drugs are delivered via many portals 
into the body using a variety of dosage forms which allow 
medicines administration. Relatively recent pharmaceuti-
cal development is the delivery of drug via the lung. The 
onset of action from this route is relatively fast compared 
with the oral & external routes of administration. Metered 
dose inhalers were most widely used in the treatment of 
respiratory airway diseases (Bisgard et al., 2002; Williams 
et al., 2008). Metered dose inhaler was first introduced in 
1950s by Ricker laboratories with chlorofluorocarbons 
propellants. All MDIs marketed prior to 1995 contained 
chlorofluorocarbons (CFC) as a propellant. CFC propel-
lants damage the ozone layer present in stratosphere, which 
protects the earth from ultraviolet radiation by filtering the 
ultraviolet-B radiation from the sun. Their production has 
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been banned since 1996 under the terms of the Montreal 
protocol (1994) and alternative formulation (Dry powder 
formulations and hydrofluroalkane (HFA) propellant based 
MDI formulations) development was started to replace the 
CFC formulations and to protect the ozone layer. Some re-
formulated metered dose inhalers are designed to improve 
the proportion of drug delivered into the lungs and to reduce 
the dose. Dry powder inhalers (DPIs) are devices through 
which a dry powder form of an active drug is delivered for 
local or systemic effect via the pulmonary route.
Beclomethasone dipropionate is indicated for the 
maintenance and treatment of asthma. A major advance 
in asthma therapy is the development of inhalers that tar-
get the drug directly to the relevant site of inflammation. 
These formulations greatly enhance the therapeutic index 
of the drugs, substantially diminishing the incidence of 
side effects without altering clinical utility (Sweetman, 
2009; Merck index)
The performance of dry powder inhaler was depend-
ed on the morphology of carrier. The influence of carrier 
roughness on performance of dry powder inhalers was 
studied (Saint-Lorant et al., 2007; Flament et al., 2004). 
The metered dose inhalers of beclomethasone dipropionate 
were developed with propellant R 134a (Hartwig et al., 
1998; Michael et al., 1996).
Beclomethasone dipropionate dry powder inhalers 
were formulated with different grades of fine and coarse 
lactose. Beclomethasone MDIs were prepared by incor-
porating overdoses, overages and different proportions of 
alcohol. The effect of formulation variables on efficiency 
of DPIs and MDIs studied and results are reported herein.
MATERIAL AND METHODS
Beclomethasone dipropionate, various grades of 
lactose monohydrate (alctoste), HFA 134a (Zephex 134a), 
alcohol, Bespack metered valves, Bespack actuators were 
collected from NATCO, Hyderabad.
Dosage unit sampling apparatus (Erweka), Anderson 
cascade impactor (Mark-II, Erweka), Twin stage impinger 
(Erweka), High performance liquid chromatography 
(Empower, Waters), Vacuum pump (Erweka), Flow me-
ter (Erweka), Pamasol filling crimping machine (P2005, 
Pamsol ), and Capsules partial filling machine (AF25(T), 
Pham) were used in this investigation.
Formulation of DPI
An accurately weighed amount of beclomethasone 
dipropionate (particle size>5µ) was blended in poly bag 
for 5 minutes separately in each case with different quanti-
ties/various grades of lactose of monohydrate in geometric 
progress. The blend was passed through 60# mesh and 
filled in to size “3” hard gelatin capsules with partial fill-
ing manual capsule filling machine. The total fill weight 
of capsule is 25 mg per capsule.
Beclomethasone dipropionate (200 mg) formulations 
were prepared with 0-20% of overages. DPI was also pre-
pared with different proportions of fine lactose (0, 5, 10, 
15, 20 and 30%) and coarse lactose. Further the inhalers 
containing two different grades of fine lactose (10%) and 
90% of coarse lactose and inhalers containing various 
grades of coarse lactose along with 10% fine lactose were 
also prepared.
Formulation of HFA based MDI
An accurately weighed 40 mg (equivalent to 200 
doses to deliver 200 mg/dose) of beclomethasone dipro-
pionte was dissolved in 1.6 g of alcohol, transferred in to 
aluminum cans crimped with metered valve by Pamasol 
2005 and filled with the 16.4 g of HFA 134a by Pamasol 
2005 propellant filling machine ( pressure filling method). 
Beclomethasone dipropionate HFA MDI 200 mg 
formulations were prepared with overdoses (0-15%) to 
study the effect of extra doses on valve delivery. The effect 
of overages on emitted dose was also studied from these 
formulations by incorporating the (0-20%w/w) overages to 
the MDI formulation containing 15% overdose. To study 
the effect of alcohol on spray pattern, leak rate, alcohol 
ranging from 0-20%w/w was incorporated in the metered 
dose inhaler formulations.
Evaluation
Drug compatibility studies
The compatibility of beclomethasone with lactose, 
alcohol and HFA was investigated with HPLC technique 
developed and validated in our Institution. Accurately 
20 mg of beclomethasone was weighed and transferred 
into 100 mL volumetric flask. The drug was dissolved in 
60 mL of methanol:water (70:30) mixture (mobile phase). 
It was sonicated and diluted with the mobile phase up to 
the mark. The resulting solution was suitably diluted and 
injected into the Nova-pak C18 (3.9 mm x 150 mm, 4 µ) 
column maintained at 30 °C. The flow rate of mobile phase 
was maintained at 1.5 mL/min for 9 min runtime. The 
sample was detected at 239 nm. 
Evaluation of dry powder inhaler formulations
The formulated DPI were evaluated for following 
parameters.
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Physical appearance
The capsules were visually inspected to identify the 
defects.
Average fill weight per capsule
Twenty capsules are collected randomly and their 
collective weight were recorded as W1.The contents of 20 
capsules were removed and the weight of the empty cap-
sule shells was determined as W2. The difference between 
those two weights was the fill weight of 20 capsules. The 
average fill weight per capsule was determined with the 
following formulae
Assay (drug content determination)
Drug content was determined by HPLC technique. 
The samples containing equivalent to 200 mg of beclo-
methasone collected from 20 capsules were analyzed for 
drug content (Indian Pharmacopoeia, 2007).
Content uniformity
This test was performed on 10 capsules. Each cap-
sule was transferred separately into a volumetric flask and 
the shell and the contents of the capsule were treated with 
5 mL of water followed by a solvent mixture of 25 mL of 
methanol: water (70:30) mixture (diluent), sonicated for 
10 minutes with intermittent shaking (for complete disper-
sion) and the volume was made up to 50 mL with diluent. 
It was then filtered through a 0.45 µ membrane filter and 
the samples were analyzed by using HPLC technique for 
drug content. The same procedure was repeated for the 
remaining 9 capsules.
Uniformity of the delivered dose and emitted dose
Uniformity of the delivered and emitted dose was 
determined according to the official procedure specified 
in Indian Pharmacopoeia (2007). The samples were ana-
lyzed with HPLC technique. These tests were performed 
repeatedly with 10 capsules in each case.
Fine particle dose
Fine particle dose (FPD) was determined by em-
ploying the procedure specified in Indian pharmacopoeia 
(2007) with the Andersen cascade impactor. The differ-
ent sample sizes (10, 15 & 20 capsules) were employed 
and the amount of fines retained in different stages was 
eluted with acetonitrile and the samples were analyzed 
using HPLC technique. The Mass Median Aerodynamic 
Diameter (MMAD) and Geometric Standard Deviation 
(GSD) were calculated using following formulae:
MMAD = Particle size at 50% cumulative mass
GSD = (Size X/SizeY) 1/2 = (MMAD/Size Y) = (Size X/
MMAD)
Size X = Particle size at 84.13% cumulative mass
Size Y = Particle size at 15.87% cumulative mass
Stability studies
The optimized beclomethasone dipropionate DPI 
formulations were stored at 40 °C/75% RH and 25 °C/60% 
RH for six months as per IGH guidelines. Later, the for-
mulations were evaluated for assay of number of doses 
delivered, deposition of emitted dose and net fill weight. 
The observed data were compared with the initial results.
Evaluation of Metered dose inhaler formulations
The formulated MDI were evaluated for following 
parameters:
·	 Physical appearance
The inhalers were visually observed to identify the defects.
·	 Drug content determination
The first 10, middle 10 and on the last 10 deliveries 
were collected from the container and the drug content of 
these deliveries were estimated. The MDI was agitated 
for 30 s and kept them in inverted position in the beaker 
containing diluent (acetonitrile: water (60:40)). Ten de-
liveries were discharged in the beaker at intervals of 15 
seconds. The retained contents from the MDI were col-
lected by washing the MDI device with the diluent and the 
contents, washings were suitably diluted and analyzed by 
using HPLC technique.
·	 Uniformity of the delivered and emitted dose
The uniformity of the delivered and emitted dose 
were determined according to the official procedure speci-
fied in Indian Pharmacopoeia (2007). The sampling device 
was agitated vigorously for 2 min and the required number 
of emitted doses delivered from the valve was collected, 
transferred in to a 100 mL volumetric flask. The tube was 
washed twice using the diluent and then the contents were 
transferred to a 100 mL volumetric flask. The final volume 
was made up to the mark with diluents, sonicated for 5 
minutes and filtered through 0.45 µ membrane filter. The 
same procedure was repeated on nine other containers. The 
samples were analyzed with HPLC technique.
·	 Fine particle dose
Fine particle dose (FPD) emitted from the MDI was 
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determined by employing Andersen cascade impactor, 
as specified in Indian pharmacopoeia (2007). The fines 
retained in different stages were eluted with acetonitrile 
and the samples were analyzed using HPLC technique.
·	 Number of doses delivered
The contents of the MDI were discharged by actu-
ating the valve at an interval of not less than 5 seconds 
and the number of doses discharged from the MDI was 
observed. 
·	 Leak test
Randomly 12 aerosol containers were selected, and 
the date and time was recorded to the nearest half-hour. 
The container was weighed and the weight was recorded 
in mg in each case and denoted as W1. The containers were 
allowed to stand in upright position at room temperature 
for a period of three days. Then the weight of the container 
was observed in mg in each case denoted as W2. The time 
interval observed in between W1 and W2 was considered 
as time interval T. The leakage rate was calculated in mg 
per year by using the formulae:
·	 Spray pattern
The contents of the pressurized container were 
sprayed on a glass slide and the spray pattern was observed 
for shape and dimensions.
·	 Valve delivery
The aerosol container with a clean actuator was 
weighed and the weight was recorded. The actuator was re-
moved and replaced with another actuator and a dose was 
dispensed. It was again replaced with the original clean 
actuator and re-weighed. The weight of each individual 
dose dispensed was recorded. The same procedure was 
repeated on another nine containers. The average weight 
of the dose delivered through the valve was calculated and 
reported as valve delivery (Cummings, 1999; McDonald 
et al., 2000).
·	 Stability studies
Beclomethasone dipropionate HFA MDI 200 mcg 
packed in aluminum cans were stored at 40 °C/75% RH 
and 25 °C/60% RH for a period of six months as per 
IGH guidelines and evaluated for assay, number of doses 
delivered, deposition of emitted dose and net fill weight. 
The samples were collected and analyzed at regular time 
intervals. The data were compared with the initial results.
RESULTS AND DISCUSSION
Drug compatibility studies with excipients were 
conducted by HPLC methods and results indicated the 
presence of identical chromatograms and were found to 
be compatible. 
Physical properties such as bulk density, tapped 
density and particle size of various lactose grades were 
evaluated and showed in Table I. Based on the flow prop-
erties lactose grades can be as Lactohale 300 < Sorbolac 
400 < Respitose SV003 < Flowlac 100 < Inhalac 230 < 
DCL11. Lactohale 300 and Sorbolac 400 alone are not 
suitable as carriers for dry powder inhalers; hence they 
were blended with coarse lactose to improve the flow 
properties.
The influence of overages in dry powder was carried 
out on beclomethasone dipropionate DPI. All the formula-
tions were formulated with 0-20% extra quantity of active 
ingredient. The observed data indicated 8-10% of drug 
retention in capsule, 3-6% of drug deposition in device 
and 84-88% of the dose was emitted from the device. To 
TABLE I - Physical properties of lactose grades used in DPI formulations
Lactose grade Bulk density 
(g/cc)
Tapped density 
(g/cc)
Hausner’s 
ratio
Carr’s 
index (%)
Particle size
(90% particles 
less than) (µ)
DCL11 0.614 0.720 1.19 15 250
Sorbolac 400 0.360 0.780 2.16 54 30
Inhalac 230 0.640 0.760 1.19 16 230
Respitose SV003 0.635 0. 780 1.22 19 100
Lactohale 300 0.350 0.770 2.20 55 10
Flowlac 100 0.600 0.730 1.21 18 220
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FIGURE 1 - Histograms correlating emitted dose and overages of beclomethasone dipropionate DPI 200 µg.
overcome these problem 20% overages is recommended in 
dry powder inhaler formulations to deliver 100% of active 
ingredient from the dry powder inhaler and to prevent in 
evitable retentive losses in DPI device. The emitted dose 
was increased with respect to the overages and results are 
shown in Figure 1. The emitted dose (delivered dose) was 
within the ICH limits (80-120%). The experiments were 
conducted in triplicate and the observed mean and standard 
deviation values are shown in Figure 1.
Beclomethasone dipropionate metered dose inhal-
ers were incorporated with extra doses (10% and 15%) 
to study the effect of extra doses on valve delivery. The 
observed mean valve delivery rates (n=3) are shown in 
Figure 2. It was observed that 230 doses are needed to 
deliver the required 200 metered doses. The additional 
doses required were found to be15% i.e 30 extra doses.
Further, the effect of overages on emitted dose was 
also studied from those formulations by incorporating 
overages (0-20%w/w) to the MDI formulation containing 
15% overdose. 20% overages are needed for 100% drug 
delivery and to prevent the inevitable retained loses either 
from the inhaler device or from the valve. The observed 
mean emitted doses (n=3) in presence of overages are 
shown in Figure 3. Thus an additional 35% of the formu-
FIGURE 2 - Effect of extra dose on valve delivery from beclomethasone dipropionate MDI containing 200 doses.
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lation more than labeled claim is required to deliver the 
specified doses completely from the MDI device.
Studies were carried out to evaluate the effect of 
concentration of fine lactose sorbolac S400 (0-30%) and 
coarse lactose Inhalac 230 on performance of DPI. All 
the formulations showed good content uniformity. Aero-
dynamic particle size is a key parameter for all inhaled 
products, directly influencing regional deposition in the 
lungs and respiratory tract. Its measurement is therefore 
critical during the product development cycle and for 
quality control. Various sizing techniques are available, 
but cascade impaction is the method specified for regula-
tory approval, and hence the most widely used Cascade 
impactors, including the multi-stage liquid impinger, are 
by far the most widely encountered means for the in vitro 
determination of the particle size distribution of aerosols 
from medical inhalers, both in product development, 
batch release and in applications with add-on devices. 
This is because they directly measure aerodynamic size, 
which is the most relevant parameter to describe particle 
transport within the respiratory tract. At the same time, it 
is possible to quantify the mass of active pharmaceutical 
ingredient in different size ranges independent of other 
non-physiologically active components of the formulation 
(Mitchell, 2003). A significant difference was noticed in 
the emitted dose and fine particle deposition with respect 
to composition of the formulation. The emitted dose was 
found to be decreased with increasing concentration of 
fine lactose and the fine particle deposition was increased 
with the incorporation of fine lactose (Table II).The mean 
of three observations along with the standard deviation 
values are shown in the following table. The low sd values 
FIGURE 3 - Effect of overages on beclomethsaone dipropionate MDI.
TABLE II - Characterization of DPI formulation with various portions of fine lactose
Beclomethasone dipropionate DPI 200 mg
% of fine 
lactose
Parameters
Content uniformity 
(% based on average) ( –x±sd)
Weight variation 
(mg)
Assay 
(%)
Emitted dose 
(%) ( –x±sd)
Fine particle Dose 
(%) ( –x±sd)
0 95.7-115.6 75.3-79.4 121.7 101.2 ± 6.1 7.9 ±1.6
5 91.7-109.3 76.3-79.6 116.6 98.6 ± 5.6 12.5 ± 0.9
10 94.6-112.0 72.7-82.4 109.4 97.8 ± 2.9 14.5 ± 0.8
15 97.5-106.1 72.4-76.9 109.6. 91.3 ± 5.8 15.1 ± 1.6
20 97.7-112.3 79.6-82.4 104.4 86.4 ± 6.7 15.0 ± 1.2
30 90.3-116.9 71.0-76.4 118.6. 75.9 ± 9.4 16.2 ± 2.0
–x = Mean of 3 values; ± = Indicates the values above or below the mean value
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TABLE III - Physical tests and drug distribution data from beclomethasone dipropionate DPI formulated with different grades of 
fine lactose
Parameter
Beclomethasone dipropionate
µg per Capsules
Sorbolac 400 Lactohale 300
Content uniformity (% based on average) 84.9-109.4 91.8-109.0
Weight variation in mg 72.0-78.7 70.9-79.9
Assay (%) 108.1 114.4
Upper Chamber 183.2 ± 7.5 135.2 ± 6.7
Lower Chamber 31.2 ± 2.7 55.8 ± 3.1
Capsule 15.8 ± 1.6 21.8 ± 2.1
Device 7.6 ± 1.3 14.2 ± 1.4
Total dose 237.8 ± 6.2 227.0 ± 7.1
Emitted dose 214.4 ± 5.8 191.0 ± 6.4
in the parameters as emitted dose and fine particle dose 
indicates that the results are reproducible.
Thus the proportion of fine and coarse lactose influ-
ences the performance of dry powder inhalers. Finally 
it is concluded that 10% of fine lactose and 90% coarse 
lactose is suitable as carrier for development of dry powder 
inhaler. 
Effect of various fine lactose grades (Lactohale 300 
and Sorbolac 400) on performance of dry powder formu-
lation was evaluated. All the formulations were tested 
for weight variation, assay, content uniformity of dose, 
emitted dose, uniformity of delivered dose; fine particle 
fraction (Lung deposition) and the mean results along with 
range/standard deviation values are shown in Table III. All 
the formulations complied content uniformity of emitted 
dose and content of active ingredient, however significant 
difference in fine particle fraction were observed with re-
spect to lactose grades. Lactohale 300 showed better fine 
particle fraction than Sorbolac 400.
Effect of various coarse lactose grades on 
performance of dry powder formulation was studied. 
All the formulations satisfied requirements of the 
content uniformity of emitted dose and content of active 
ingredient. The mean fine particle fraction (n=3) observed 
from DPI formulated with different lactose grades is 
shown in Figure 4. Respitose SV003 showed better 
fine particle fraction than other coarse lactose grades 
(Inhalac230, DCL11 and Flowlac100).
The alcohol may alter the vapor pressure of propel-
lant, solubility of the drug in the propellant and hence 
spray pattern from the actuator may vary in metered dose 
inhalation formulation. The effect of alcohol on spray pat-
tern and other parameters was studied and experimental 
FIGURE 4 - Effect of coarse lactose grade on lactose grade on 
beclomethasone diprionate DPI performance.
results are shown in Table IV. Lower concentrations of 
alcohol resulted in low valve delivery and higher concen-
tration exhibited more leak rate. Hence, optimum alcohol 
concentration (5-10%w/w) is necessary for effective valve 
delivery and lower leak rate.
The HFA based beclomethasone dipropionate MDIs 
of 100 mg & 200 mg were evaluated for leak rate, valve de-
livery, net fill weight and spray pattern. The experimental 
results indicated the leak rate of 2.1 ± 0.3 & 1.8± 0.1% per 
year, valve delivery of 63 ± 4 & 64 ± 6 mg, net fill weight 
of 17.0 ± 0.2& 17.2 ± 0.3 g and spray pattern of 12.1 ± 0.2 
& 12.5 ± 0.2 mm.
MDI formulations were evaluated for emitted dose 
and fine particle fraction with twin impinger apparatus and 
samples were analyzed with HPLC technique. Emitted 
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dose, fine particle fraction were inversely proportional to 
alcohol content and indicated that the 5-10%w/w alcohol 
content is preferred to get optimum emitted dose and fine 
particle fraction and results were given in Figure 5.
Drug distribution in various stages was observed 
with 10, 15 and 20 capsules of beclomethasone dipro-
pionate DPI in Anderson cascade impactor and beclo-
methasone dipropionate HFA MDIs containing 0.33 mm 
diameter actuator were tested for particle size distribution 
with Anderson cascade impactor. The observed mean drug 
distribution pattern in various stages of cascade impactor 
given is in Table V. The retentive losses were found to be 
less in sample size 20 capsules.
Fine particle fraction and emitted dose were bet-
ter with 20 capsules sample size when compared with 
10 and 15 samples size (Table VI) and drug distribution 
pattern was observed. There is no correlation observed in 
between sample size and Anderson cascade data. Good 
recovery was observed for beclomethasone dipropionate 
with sample size 20.
The stability studies were carried out as per ICH 
guidelines for HFA based MDI formulations of beclo-
methasone 200 mg and beclomethasone DPI formulations 
stored at 40 °C/75% RH and 25 °C/60%RH as per ICH 
guidelines and results showed that these products are 
stable at 25 °C/60%RH (Table VII and Table VIII).
CONCLUSION
Dry powder inhalers and HFA based metered dose 
inhalers are developed for beclomethasone dipropionate. 
The performance of dry powder inhaler is found to be 
dependent on overages, proportion of fine and coarse 
lactose and the lactose grade employed in the preparation 
TABLE IV - Characterization of MDI formulated with various concentrations of alcohol
% alcohol Leak rate (% per year) Valve delivery (mg) Net fill weight (g) Spray pattern (mm)
0 2.1 ± 0.1 63 ± 4 17.0 ± 0.2 12.1 ± 0.2
2.5 1.8 ± 0.3 64 ± 5 17.2 ± 0.3 12.5 ± 0.3
5.0 1.9 ± 0.2 68 ± 3 17.5 ± 0.2 13.1 ± 0.2
7.5 1.5 ± 0.3 64 ± 5 17.6 ± 0.4 13.2 ± 0.3
10.0 1.9 ± 0.2 62 ± 6 17.6 ± 0.3 14.5 ± 0.1
15.0 1.9 ± 0.1 64 ± 3 17.2 ± 0.4 14.6 ± 0.2
20.0 2.1 ± 0.2 64 ± 9 17.0 ± 0.3 15.9 ± 0.3
n 3 10 5 10
n: Number of replication
FIGURE 5 - Effect of alcohol content on ED and FP from beclomethasone dipropionate HFA MDI 100 mg.
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TABLE V - Anderson cascade distribution with various sampling sizes of beclomethasone dipropionate DPI 200 mg and 
beclometasone MDI 200 mg
Sample size
µg/capsule ( Average of three trials) Beclomethasone 
HFA MDI 
200 µg10 capsules 15 capsules 20 capsules
Device 16.21 ± 1.5 18.64 ± 1.1 16.10 ± 1.5 --
Capsules shells 13.40 ± 1.3 15.30 ± 0.9 10.30 ± 1.4 --
Induction port 90.00 ± 6.7 78.00 ± 8.4 75.00 ± 8.9 70 ± 0.2
Pre-separator 50.00 ± 4.2 65.00 ± 6.7 70.00 ± 8.1 --
Stage 0 28.71 ± 1.2 30.10 ± 2.8 27.60 ± 3.1 2.4 ± 0.1
Stage 1 14.84 ± 2.1 11.56 ± 1.6 16.89 ± 2.1 2.2± 0.2
Stage 2 7.44 ± 0.8 8.15 ± 1.1 7.69 ± 2.4 2.0 ± 0.2
Stage 3 11.81 ± 1.3 12.56 ± 1.7 10.96 ±1.8 1.2 ± 0.05
Stage 4 6.13 ± 0.9 6.18 ± 0.9 7.21 ± 1.1 1.6 ± 0.1
Stage 5 2.34 ± 0.2 2.34 ± 0.4 2.84 ± 0.6 2.2± 0.1
Stage 6 0.39 ± 0.05 0.32 ± 0.08 0.34 ± 0.05 33.0 ± 0.4
Stage 7 1.85 ± 0.04 1.53 ± 0.12 1.65 ± 0.2 32.4± 0.1
Filler 0.00 ± 0 0.08 ± 0.02 0.01 ± 0.0 29.0 ± 0.5
Capsules shells + device 29.61 ± 2.4 33.94 ± 3.6 26.40 ± 2.8 --
TABLE VI - Effect of sample size on cascade impactor testing of beclometasone DPI
Product Beclomethasone DPI 200 µg
Sample size (capsules) 10 15 20
% FPF 14.98 ± 1.2 15.58 ± 2.1 15.35 ± 1.5
% of Emitted dose 106.76 ± 6.4 107.91 ± 5.8 110.10 ± 5.2
% of Total Dose 121.56 ± 5.9 124.88 ± 5.6 123.30 ± 6.2
MMAD 7.87 ± 0.2 7.45 ± 0.3 6.46 ± 0.2
GSD 3.31 ± 0.2 2.65 ± 0.1 2.34 ± 0.1
% Based on the Label Amount (LA)
TABLE VII - Stability data of Beclomethasone DPI 200 µg stored at 40±2 °C/75±5% RH & 25±2 °C/60±5% RH
Storage condition : 40±2 °C / 75±5% RH
# Characteristics tested
Results at testing intervals
Initial 1 month 2 months 3 months 6 months
1 Description Complies Complies Complies Complies Complies
2 Assay (%) 114.3 112.2 108.5 111.2 114.8
3 Deposition of emitted dose (%) 15.7 16.2 17.8 16.9 15.5
Storage condition : 25±2 °C/60±5% RH
# Characteristics tested
Results at testing intervals
Initial 3 months 6 months 9 months 12 months
1 Description Complies Complies Complies Complies Complies
2 Assay (%) 114.3 112.9 114.0 113.0 113.9
4 Deposition of emitted dose (%) 15.7 16.1 15.8 15.3 15.9
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TABLE VIII - Stability data of Beclomethasone HFA based MDI 200 mg stored at 40±2 °C/75±5% RH & 25±2 °C/60±5% RH
Storage condition : 40±2 °C/75±5% RH
# Characteristics tested
Results at testing intervals
Initial 1 months 2 months 3 months 6 months
1 Description Complies Complies Complies Complies Complies
2 Assay (%) 116.3 115.2 108.5 111.2 114.8
3 No. of doses 229 226 234 227 224
4 Deposition of emitted dose (%) 38.8 39.9 48.6 44.6 42.7
5 Net fill weight (g) 37.6 37.2 36.0 35.2 35.4
Storage condition : 25±2 °C/60±5% RH
# Characteristics tested
Results at testing intervals
Initial 3 months 6 months 9 months 12 months
1 Description Complies Complies Complies Complies Complies
2 Assay (%) 116.3 114.9 116.0 113.0 113.9
3 No. of doses 229 232 225 232 230
4 Deposition of emitted dose (%) 38.8 40.1 38.9 42.0 39.1
5 Net fill weight (g) 37.0 37.2 37.0 36.2 36.4
of dry powder inhalers. The performance of dry powder 
inhalers containing beclomethasone dipropionate was 
found to be optimum when the DPI is formulated with 
10:90 ratio of fine lactose (Lactohale 300):coarse lactose 
(Respitose SV003) and having 20% w/w overages. In 
pressurized metered dose inhalation formulation, over-
ages are required to reach the 100% of target amount 
drug to the patient. An extra 20% is recommended in the 
formulation. All the developed metered dose inhalers met 
the pharmacopoeial requirements. The formulations are 
stable at recommended storage conditions i.e. 25 °C/60% 
RH. This investigation successfully yielded an alterna-
tive CFC metered dose inhaler for effective delivery of 
beclomethasone dipropionate.
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